Interv Akut Kardiol 2011; 10(5-6): 219-222

Percutaneous exclusion of the left atrial appendage in preventing systemic embolization

Josef Šťásek1, Josef Bis1, Zdeněk Vavera1, Jan Vojáček1, Jaroslav Dušek1, Petr Pařízek1, Miroslav Brtko2, Pavel Polanský2, Dušan Černohorský3
1 I. interní kardioangiologická klinika, 2Kardiochirurgická klinika, 3Klinika gerontologická a metabolická
Univerzita Karlova v Praze, Lékařská fakulta Hradec Králové a Kardiocentrum Fakultní nemocnice Hradec Králové

Left atrial appendage is the most frequent place of a formation of blood clots in heart cavities. Thrombus formation increases the risk

of a systemic embolism. The standard preventive treatment is an oral anticoagulant therapy. Another possibility of a treatment is an

elimination of a left atrial appendage. We present current overview of a risk and possibilities of surgical and percutaneous elimination

of a left atrial appendage. We present the first experience with percutaneous elimination of a left atrial appendage by AMPLATZER

Cardiac Plug system.

Keywords: left atrial appendage, systemic embolism, atrial fibrillation

Published: November 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šťásek J, Bis J, Vavera Z, Vojáček J, Dušek J, Pařízek P, et al.. Percutaneous exclusion of the left atrial appendage in preventing systemic embolization. Interv Akut Kardiol. 2011;10(5-6):219-222.
Download citation

References

  1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed a trial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001; 285: 2370-2375. Go to original source... Go to PubMed...
  2. Crystal E, Connolly SJ. Role of oral anticoagulation in management of atrial fibrillation. Heart. 2004; 90: 813-817. Go to original source... Go to PubMed...
  3. Atrial Fibrillation Investigators: Atrial Fibrillation, Aspirin Anticoagulation Study, et al. Risk factors for stroke and efficacy of antithrombotic therapy in a trial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154: 1449-1457. Go to original source...
  4. Onalan O, Crystal E. Left atrial appendage exclusion for stroke preventionin patients with non-rheumatic atrial fibrillation. Stroke 2007; 38(2): 624-630. Go to original source... Go to PubMed...
  5. Blackshear JL, Odell JA. Append age obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann ThoracSurg. 1996; 61: 755-759. Go to original source... Go to PubMed...
  6. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999; 131: 492-501. Go to original source... Go to PubMed...
  7. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrilation. Ann Intern Med. 2007; 146: 857-867. Go to original source... Go to PubMed...
  8. ACTIVE Writing Group ofthe ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S. Clopidogrel plus Aspirin versus oral anticoagulation for a trial fibrilation in the Atrial Fibrilation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367: 1903-1912. Go to original source... Go to PubMed...
  9. Holmes DRJr, Schwartz RS. Left a trial appendage occlusion eliminates the need for warfarin. Circulation. 2009; 120(19): 1919-1926; discussion 1926. Go to original source... Go to PubMed...
  10. Onalan O, Lashevsky I, Hamad A, Crystal E. Nonpharmacologic stroke prevention in atrial fibrillation. Exp Rev Cardiovasc Ther. 2005; 3: 619-633. Go to original source... Go to PubMed...
  11. Kanderian AS, Gillinov AM, Pettersson GB, Klein AL. Success of surgical left atrial appendage occlusion techniques assessed by transes ophageal echo cardiography. J AmCollCardiol. 2006; 47: 152A.
  12. Garcia-Fernandez MA, Perez-David E, Quiles J, Peralta J, Garcia-RojasI, Bermejo J, Moreno M, Silva J. Role of left a trial append age obliteration in stroke reduction in patients with mitral valve prosthesis: a transes ophageal echo cardiographic study. J AmCollCardiol. 2003; 42: 1253-1258. Go to original source... Go to PubMed...
  13. Crystal E, Lamy A, Connolly SJ, Kleine P, Hohnloser SH, Semelhago L, Abouzhar L, Cybulsky I, Shragge B, Teoh K, Lonn E, Sawchuk C, Oezaslan F. Left a trial append age occlusion study (LAAOS): a randomized clinical trial of left a trial appendage occlusion during routine coronary artery bypass graft surgery for longterm stroke prevention. AmHeart J. 2003; 145: 174-178. Go to original source...
  14. Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH, Cybulsky I, Abouzahr L, Sawchuck C, Carroll S, Morillo C, Kleine P, Chu V, Lonn E, Connolly SJ. Left a trial appendage occlusion study (LAAOS): results of a randomized controlled pilot study of left a trial appendage occlusion during coronary bypass surgery in patients at risk for stroke. AmHeart J. 2005; 150: 288-293. Go to original source...
  15. Katz ES, Tsiamtsiouris T, Applebaum RM, Schwartzbard A, Tunick PA, Kronzon I. Surgical left atrial append age ligationis frequently incomplete: a transes ophageal echo cardiograhic study. J AmCollCardiol. 2000; 36: 468-471. Go to original source... Go to PubMed...
  16. Odell JA, Blackshear JL, Davies E, Byrne WJ, Kollmorgen CF, Edwards WD, Orszulak TA. Thoracoscopic obliteration of the left atrial appendage: potential for stroke reduction. Ann Thorac Surg. 1996; 61: 565-569. Go to original source... Go to PubMed...
  17. Blackshear JL, Johnson WD, Odell JA, Baker VS, Howard M, Pearce L, Stone C, Packer DL, Schaff HV. Thoracoscopic extra cardia cobliteration of the left atrial appendage for stroke risk reduction in a trial fibrillation. J Am Coll Cardiol. 2003; 42: 1249-1252. Go to original source... Go to PubMed...
  18. Kamohara K, Fukamachi K, Ootaki Y, Akiyama M, Zahr F, Kopcak MW, Dessoffy R, Popovic ZB, Daimon M, Cosgrove DM, Gillinov AM. Anovel device for left atrial appendage exclusion. J Thorac CardiovascS urg. 2005; 130: 1639-1644. Go to original source... Go to PubMed...
  19. Wolf RK, Schneeberger EW, Osterday R, Miller D, Merrill W, Flege JBJr, Gillinov AM. Video-assisted bilateral pulmonary veinisolation and left atrial appendage exclusion for atrial fibrillation. J Thorac Cardiovasc Surg. 2005; 130: 797-802. Go to original source... Go to PubMed...
  20. Balkhy HH, Chapman PD, Arnsdorf SE. Minimally invasive a trial fibrillation ablation combined with a new technique for thoracoscopic stapling of the left atrial appendage: case report. Heart Surg Forum. 2004; 7: 353-355. Go to original source... Go to PubMed...
  21. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left a trial appendage trans catheter occlusion to prevent stroke in high-risk patients with atrial fibrillation - early clinicalexperience. Circulation. 2002; 105: 1887-1889. Go to original source... Go to PubMed...
  22. Nakai T, Lesh MD, Gerstenfeld EP, Virmani R, Jones R, Lee RJ. Percutaneous left a trial appendage occlusion (PLAATO) for preventing cardioembolism: first experience in canine model. Circulation. 2002; 105: 2217-2222. Go to original source... Go to PubMed...
  23. Meier B, Palacios I, Windecker S, Rotter M, Cao QL, Keane D, Ruiz CE, Hijazi ZM. Transca the terleft atrial appendage occlusion with Amplatzer devices to obviate antico agulation in patients with atrial fibrillation.
  24. Stöllberger C, Schneider B, Finsterer J. Elimination of the left atrial appendage to prevent stroke or embolism? Anatomic, physiologic, and pathophysiologic considerations. Chest. 2003; 124(6): 2356-2362. Go to original source... Go to PubMed...
  25. Ostermayer SH, Reisman M, Kramer PH, et al. Percut aneous left a trial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patientswith non-rheumatic atrial fibrillation: results from the international multicenter feasibility trials. J AmCollCardiol. 2005; 46: 9-14. Go to original source... Go to PubMed...
  26. Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left a trial appendage system for stroke prevention in atrial fibrillation. J AmCollCardiol.2007; 49: 1490-1495. Go to original source... Go to PubMed...
  27. Park JW, Bethencourt A, Sievert H, Santoro G, Meier B, Walsh K, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial Europe anexperience. Catheter Cardiovasc Interv. 2011; 77(5): 700-706. Go to original source... Go to PubMed...
  28. Protect AF-WATCHMAN left atrial appendage system for embolic protection in patients with atrial fibrillation. Available at: www.Clinicaltrials. Gov/ct/show/nct00129545?Order_1. AccessedApril 9, 2006.
  29. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Sick P. PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009; 374(9689): 534-542. Go to original source... Go to PubMed...
  30. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of ercutaneous left atrial appendage closure: results from the Watch man Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation. 2011; 123(4): 417-424. Epub 2011 Jan 17. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.